<DOC>
	<DOCNO>NCT01068444</DOCNO>
	<brief_summary>Recent study demonstrate PPARγ well diet control could improve glycemic control , decrease serum ALT level , decrease hepatic fat distribution , increase intrahepatic insulin sensitivity . The purpose study : 1 . Primary aim : 1 . Comparison Pioglitazone placebo group term steatosis liver function test . 2 . Evaluation clinical safety Pioglitazone 2 . Secondary aim : 1 . Comparison Pioglitazone placebo group term liver necroinflammation fibrosis . 2 . The impact Pioglitazone relate metabolic index , include insulin resistance ( HOMA-IR ) , newly-onset diabetes , metabolic syndrome , lipid profile ( T-Chol , HDL-C , LDL-C , TG ) . 3 . Comparison Pioglitazone placebo group term high-sensitive C-reactive protein change . 3 . Interventional aim : Assessment association magnetic resonance imaging study intrahepatic fat distribution Pioglitazone treatment .</brief_summary>
	<brief_title>The Efficacy Safety Pioglitazone Patients With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description>Pioglitazone belong thiazolidinediones anti-diabetes drug decrease insulin resistance . It increase use glucose peripheral tissue decrease production glucose liver dose influence production insulin . It agonist peroxisome proliferator-activated receptor-gamma ( PPARγ ) bind receptor PPARγ various tissue effect transcription insulin-dependent gene . In animal model , pioglitazone show influence metabolism insulin-dependent mechanism . Recent study demonstrate PPARγ well diet control could improve glycemic control , decrease serum ALT level , decrease hepatic fat distribution , increase intrahepatic insulin sensitivity . Meanwhile , PPARγ could also prevent development alcohol-induced steatohepatitis , improve hepatic necroinflammatory activity , decrease lipid deposition . It yet clearly know effect P-PARγ agonist among Asian people .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Main inclusion criterion : 1 . Male female patient 1870 year age 2 . Liver biopsy finding consistent diagnosis NASH without compensate cirrhosis within one year baseline 3 . Compensated liver disease 4 . Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug 5 . All fertile male female must use two form effective contraception treatment 3 month treatment . 6 . ALT level 1.35 x ULN 2 occasion 6 month screen . 7 . HbA1C ≦ 8.0 screen Main exclusion criterion : 1 . Therapy systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) *6 month baseline . 2 . History evidence medical condition associate chronic liver disease NASH ( e.g. , hemochromatosis , autoimmune hepatitis , alcoholic liver disease , &gt; 20 g/day female &gt; 40 g/day male , toxin exposure ) 3. hepatocellular carcinoma 4 . History evidence bleed esophageal varix condition consistent decompensated liver disease 5 . Serum creatinine level &gt; 1.5 time upper limit normal screening calculate creatinine clearance calculate Cockcroft Gault &lt; 60mL/min screen 6 . History ischemic heart disease screen 7 . New York Heart Association ( NYHA ) Functional Class 14 cardiac status screen 8 . Albumin &lt; 3.2g/dL screen 9 . Total bilirubin &gt; 1.2 x ULN screen . Patients history asymptomatic indirect hyperbilirubinemia whose total bilirubin &lt; 2 x ULN direct bilirubin &lt; 20 % total bilirubin could include . 10 . History prothrombin time &gt; 15 second International normalize ratio ( INR ) &gt; 1.3 11 . Organ , stem cell , bone marrow transplant 12 . History serious concurrent medical illness investigator 's opinion might interfere therapy include significant systemic illness ( liver disease ) chronic pancreatitis 13 . Active systemic autoimmune disorder 14 . Pregnancy ( lactation ) , subject capable bearing child , inability / unwillingness practice adequate contraception 15 . Females childbearing potential ( postpuberty ) unwilling unable pregnancy test study visit 16 . Therapy systemic antiviral agent ( exception prophylaxis treatment influenza chronic HSV ) within past 30 day prior screen . 17 . Concurrent participation another clinical trial subject expose another investigational noninvestigational drug device within 6 week screen visit 18 . Current therapy insulin within 1 week prior screen . 19 . Experienced use PPARg agonist ( e.g. , rosiglitazone , pioglitazone ) within 6 month prior screen . 20 . Known hypersensitivity component PPARg agonists 21 . A history hepatotoxicity TZDs and/or history severe edema medically serious fluidrelated event associate use TZDs 22 . History metformin use within 3 month prior screen . 23 . Type Ⅰ diabetes 24 . Seropositive HBsAg , antiHCV antiHIV screen 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>NASH</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Treatment</keyword>
</DOC>